New trial
Phase 1 Study: Evaluating UF-KURE19 CAR-T Cells for Relapsed/Refractory B Cell NHL
- Trial ID
- NCT05400109 on ClinicalTrials.gov
- Cancer type
- Non-Hodgkin Lymphoma
- Location
- 2 Locations
- Published in
- New in Oncology - May 14, 2025
Case Western is assessing the safety and manufacturing feasibility of UF-KURE19—a CD19-targeted CAR-T cell therapy modified via a shortened lentiviral process—in patients with relapsed non-Hodgkin lymphoma (with or without prior ASCT). Participants receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide before weight-based UF-KURE19 infusion.
More in lymphoma
-
Trial result · Oct 22, 2026 · NCT04245839
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL -
Trial result · Oct 22, 2026 · NCT05800366
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL -
Trial result · Oct 15, 2026 · NCT03618550
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma -
Trial result · Oct 15, 2026 · NCT03598608
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued -
Trial result · Oct 1, 2026
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL